

# Lynn G Feun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5893986/publications.pdf>

Version: 2024-02-01

40  
papers

2,210  
citations

304743

22  
h-index

315739

38  
g-index

40  
all docs

40  
docs citations

40  
times ranked

3041  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the Prolineâ€“Glutamineâ€“Asparagineâ€“Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy. <i>Pharmaceuticals</i> , 2021, 14, 72.	3.8	28
2	Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7379.	4.1	14
3	Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7628.	4.1	3
4	An Openâ€“Label, Randomized, Multiâ€“Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukinâ€“2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. <i>Oncolmunology</i> , 2021, 10, 1984059.	4.6	2
5	Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 105-117.	3.4	33
6	Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors. <i>Translational Oncology</i> , 2020, 13, 355-364.	3.7	15
7	Single-cell analysis reveals new evolutionary complexity in uveal melanoma. <i>Nature Communications</i> , 2020, 11, 496.	12.8	268
8	Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3603-3614.	4.1	121
9	Optical coherence tomography imaging of melanoma skin cancer. <i>Lasers in Medical Science</i> , 2019, 34, 411-420.	2.1	64
10	Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 9-15.	3.7	12
11	Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. <i>Cancer Letters</i> , 2017, 388, 54-63.	7.2	32
12	Degradation of AMPKâ€“1 sensitizes BRAF inhibitorâ€“resistant melanoma cells to arginine deprivation. <i>Molecular Oncology</i> , 2017, 11, 1806-1825.	4.6	19
13	Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1297.	4.1	27
14	Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. <i>Oncotarget</i> , 2017, 8, 49275-49292.	1.8	74
15	Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1 $\beta$ , and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. <i>Oncotarget</i> , 2016, 7, 82658-82670.	1.8	33
16	BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. <i>Oncotarget</i> , 2016, 7, 17665-17680.	1.8	13
17	Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2016, 36, 3555-63.	1.1	3
18	Arginine deprivation in cancer therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2015, 18, 78-82.	2.5	65

#	ARTICLE	IF	CITATIONS
19	Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. <i>Journal of Clinical Oncology</i> , 2015, 33, 4093-4098.	1.6	120
20	Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. <i>Oncotarget</i> , 2015, 6, 6295-6309.	1.8	36
21	Advanced Extramammary Paget's Disease of the Groin, Penis, and Scrotum. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S13107.	1.3	27
22	A Case of Intracranial Hemorrhage Caused by Combined Dabrafenib and Trametinib Therapy for Metastatic Melanoma. <i>American Journal of Case Reports</i> , 2014, 15, 441-443.	0.8	16
23	Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. <i>Anticancer Research</i> , 2014, 34, 6991-9.	1.1	12
24	Arginine deprivation therapy for malignant melanoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 11.	1.2	23
25	TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. <i>Molecular and Cellular Biochemistry</i> , 2013, 374, 181-190.	3.1	66
26	Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. <i>British Journal of Cancer</i> , 2012, 106, 1481-1485.	6.4	98
27	Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells. <i>Cancer Research</i> , 2012, 72, 2622-2633.	0.9	175
28	Targeting Argininosuccinate Synthetase in Cancer Therapy. , 2012, , 37-51.		1
29	Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. <i>Oncotarget</i> , 2010, 1, 246-251.	1.8	81
30	Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 $\alpha$ /Sp4. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3223-3233.	4.1	113
31	Topoisomerase I inhibitors for the treatment of brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 707-716.	2.4	18
32	Arginine Deprivation as a Targeted Therapy for Cancer. <i>Current Pharmaceutical Design</i> , 2008, 14, 1049-1057.	1.9	197
33	The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma. <i>Drug Target Insights</i> , 2007, 2, 117739280700200.	1.4	26
34	Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2007, 82, 177-181.	2.9	15
35	The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. <i>Drug Target Insights</i> , 2007, 2, 119-28.	1.4	21
36	Pegylated arginine deiminase: a novel anticancer enzyme agent. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 815-822.	4.1	103

#	ARTICLE	IF	CITATIONS
37	Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. <i>Journal of Clinical Oncology</i> , 2005, 23, 7660-7668.	1.6	218
38	Cyclosporine A, alpha-Interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. <i>Cancer Investigation</i> , 2005, 23, 3-8.	1.3	4
39	Recombinant leukocyte interferon, doxorubicin, and 5FU in patients with hepatocellular carcinoma-A phase II trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003, 129, 17-20.	2.5	14
40	Procollagen-Like Protein as a Molecular Target in the Treatment of Primary Brain Tumor. <i>Scientific World Journal</i> , The, 2002, 2, 125-126.	2.1	0